Global 3D Printable Biomaterial Ink Market - 2023-2030

Overview

Global 3D Printable Biomaterial Ink Market reached US$ 568.7 million in 2022 and is expected to reach US$ 2,256.3 million by 2030, growing with a CAGR of 18.8% during the forecast period 2023-2030.

The global 3D printable biomaterial ink market is setting for renewed expansion as 3D printed implants become increasingly common in orthopedics and orthodontics. 3D Printed dental and orthopedic implants have become standard for the treatment of various ailments, thus providing a steady source of demand for biomaterial ink.

The long term growth potential for the global 3D printable biomaterial ink market is hobbled by declining pace of new innovation and product launches over the past few years. Without new innovations catering to the up and coming breatkthroughs in regenerative medicines and bio implants, the global market faces a risk of stagnating growth.

Dynamics

New Advances in Regenerative Medicine

Regenerative medicine has witnessed several important breakthroughs in recent years, mainly due to extensive international collaboration. From new bio materials to new therapeutic agents, many new regenerative treatments are expected to hit the market during the upcoming years. All these advances are likely to translate into renewed demand growth for 3D printable biomaterial ink over the medium and long term.

Hydrogels have become a particular area of focus, due to their pre-existing news, making them ideal for 3D printing applications. For instance, according to a research paper published by scientists from the Sixth People's Hospital, Shanghai JiaoTong University in China, hydrogels are suitable for controlled 3D printing for complex multi-tissue implants.

Stem cell therapy is another major area that is actively researched, especially due to its promising approach towards the treatment of heart diseases. New research published in December 2023, by the Mayo Clinic, a major U.S.-based hospital and research center, found that new stem cell therapy significantly improved quality of life for patients with advanced heart failure.

Growing Interest in Lab Grown Meat

Driven by the need to reduce land and water resources required for the convetional meat industry, lab grown, 3D printed meat was a popular idea adopted by a section of tech entrepreneurs. However, this obscure idea has now attracted mainstream attention and many startups are engaged in developing lab grown meat.

For instance, in June 2023, U.S. food and drug administration (USFDA) announced that it had given regulatory approval to two startups, GOOD Meat and UPSIDE Foods, to sell lab grown chicken meat in U.S. market. Furthermore, in December 2023, Steakholder, an Israeli startup, announced the development of its new 3D printed, lab grown eel meat.

Biomaterial ink is an important component of lab grown meat, where the ink is used as a binder and a filler during the printing process. The growing popularity of lab grown meat will allow ink manufacturers to develop new types of edible ink more suitable for different meat types, thus contributing to the growth of the global market.

Lengthy New Product Development Cycle

The emerging fields in which 3D printable biomaterial ink is used such as regenerative medicine and bio implants, have historically had long gestation periods. It takes years, if not decades to create a fundamentally new breakthrough innovation. Furthermore, there are a string of major regulatory approvals that are required before the products are allowed to be sold in the market.

It has been a consistent factor in hobbling the growth potential of the global market. Since a new product only comes on the market once in a while, there is no scope for radical expansion of demand for printable biomaterial ink. Furthermore, demand continues to remain stagnant for most of the time, disincentivizing biomaterial ink manufacturers from investing in capacity expansion.

Segment Analysis

The global 3D printable biomaterial ink market is segmented based on type, application and region.

New Advances in Medical Sciences

Biomedical implants are witnessing radical new innovations and could potentially generate the highest demand for printable biomaterial ink during the forecast period. One of the key advantages of bio implants is that there is low risk of implant rejection and low immunogenicity. Furthermore, depending on the requirement, the bio implant can remain within the patient's body permanently or undergo biodegradation without any risk to the patient's health.

Current biomedical research is focused on expanding the type and materials of bio implants as well as improving the overall process for bio implant manufacturing. As numerous patents get filed and regulatory approvals are obtained, the demand for printable biomaterial inks for implant manufacturing will skyrocket over the upcoming years.

Geographical Penetration

With Numerous Innovative Advances, North America Garners Top Position

North America is expected to have the highest share within the global 3D printable biomaterial ink market since it has the largest share of startups and research institutions focused on researching emerging biomedical breakthroughs. All of this is made possible by the well-ordained research-oriented academic ecosystem of U.S. universities. Furthermore, many venture capital funds and government agencies generously fund research in hopes of commercializing new breakthroughs.

Several new 3D bio implants have received regulatory approval over the course of 2023 and the future demand for printable biomaterial ink appears to be stable. For instance, in December 2023, U.S. food and drug administration (USFDA) approved Novosis Ortho, a new, 3D printed spine implant designed to accelerate bone recovery in the event of a spinal injury.

Companies are already entering into collaborative partnerships to help develop this emerging market. For instance, in April 2023, Stratasys, a 3D printing solutions provider, signed a partnership agreement with CollPlant, an Israeli-American company specializing in regenerative medicine, to develop 3D printed regenerative breast implants.

COVID-19 Impact Analysis:

The COVID-19 pandemic created several pitfalls and challenges for the global 3D printable biomaterial ink market. First and foremost, the imposition of lockdowns during the initial pandemic period disrupted research work, forcing many companies to delay and extend the launch of new products. Furthermore, uncertainty in global markets prompted many companies to abandon strenuous research areas. A stark reduction in venture capital funding also led to the bankruptcy of some emerging startups.

The difficult market conditions also created many problems for the supply of 3D printable biomaterial ink. Due to its specialist and niche nature, production was already limited before the pandemic and was further restricted since precursor materials were in short supply due to pandemic induced supply chain disruptions. The overall situation has improved in the post-pandemic period; however, the market is still likely to face challenges over the short and medium term.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine will not significantly impact the global 3D printable biomaterial ink market at large. Although the war did cause major short-term volatility in global energy markets due to severe economic sanctions on Russia, the volatility has been priced in and is unlikely to generate major concern. A temporary spike in precursor material prices led to slightly elevated prices for 3D printable biomaterial ink in the short term.

The most direct impact has been on the local 3D printable biomaterial ink markets in Ukraine and Russia. Many Ukrainian scientists fled the war and have continued their research from universities and research institutes in western Europe. Economic sanctions have led to the cessation of exports of biomaterial ink to Russian entities.

However, some Russian institutions have purchased stocks from Chinese suppliers and the grey market to continue research. Many Russian scientists opposing the war have also fled Russia, thus hobbling the long term growth potential of the domestic market due to loss of talented human capital.

By Type

• Polysaccharides
• Protein-based Bio-ink
• Synthetic Biopolymers
• Others

By Application

• Orthopedic
• Stomatology
• Regenerative Medicine
• Bio Implants
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In January 2024, Matexcel, a U.S.-based biomedical materials engineering company announced the launch of a new array of biomaterial inks for various specialized 3D printing applications.
• In October 2023, new research indicated that 3D bioprinting of complex human tissue, including fully grown organs, could become possible by the end of the decade.
• In August 2023, U.S. and Korean scientists developed a unique engineered bioink for 3D printing cancer tumor models.

Competitive Landscape

The major global players in the market include: 3D Systems, Inc., Stratasys, Evonik Industries AG, Renishaw plc., Formlabs, Envisiontec US LLC, Sandvik AB, EOS, Aspect Biosystems Ltd. and Bio Inx.

Why Purchase the Report?

• To visualize the global 3D printable biomaterial ink market segmentation based on type, application, end-user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pouch tapes market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global 3D printable biomaterial ink market report would provide approximately 46 tables, 41 figures and 187 Pages.

Target Audience 2023

• Biomedical Engineering Companies
• Implant Manufacturers
• Industry Investors/Investment Bankers
• Research Professionals